Market Place
Sourcing Support
InxMed’s Ifebemtinib Receive Breakthrough for NSCLC in China
21 Nov 2024 //
PR NEWSWIRE
InxMed Presents Data On Improving ADC Therapeutic At World ADC
07 Nov 2024 //
PR NEWSWIRE
InxMed Positive Ifebemtinib Garsorasib Data In KRAS G12C NSCLC
30 May 2024 //
PR NEWSWIRE
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
19 Dec 2023 //
PR NEWSWIRE
InxMed Releases Data Demonstrating Ifebemtinib Trending Toward Survival Benefit
22 Oct 2023 //
PR NEWSWIRE
InxMed Presents Data at 14th World ADC Highlighting Synergy of IN10018
18 Oct 2023 //
PR NEWSWIRE
InxMed Receives Approval PhI Trial China for OMTX705, a 1st-in-Class FAP ADC
29 Aug 2023 //
PR NEWSWIRE
GeneQuantum and InxMed have reached a technology licensing collaboration
17 Jul 2023 //
PR NEWSWIRE
InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in ovarian cancer
29 May 2022 //
PRNEWSWIRE
InxMed Raised $15M in Series B+ Financing
09 May 2022 //
FINSMES
InxMed Raised $15M in Series B+ Financing
08 May 2022 //
PRNEWSWIRE
InxMed FAK Inhibitor IN10018 Received BTD by NMPA
13 Apr 2022 //
PRNEWSWIRE
US FDA grants fast track designation to InxMed`s IN10018
16 Aug 2021 //
PHARMABIZ
InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing
04 Sep 2020 //
PRNEWSWIRE
InxMed Released Research Data of "FAK inhibitor IN10018 overcomes drug
23 Jun 2020 //
PRNEWSWIRE
InxMed of Shanghai Doses First Patient in US Trial of FAK Inhibitor
17 Mar 2020 //
CHINABIO TODAY
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018
16 Mar 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.